Literature DB >> 26790551

Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.

Yan Gao1,2, Yunfei Liao1, Jacson K Shen1, Yong Feng1, Edwin Choy1, Gregory Cote1, David Harmon1, Henry J Mankin1, Francis J Hornicek1, Zhenfeng Duan1.   

Abstract

Survival of osteosarcoma patients is currently limited by the development of metastases and multidrug resistance (MDR). A well-established cause of MDR involves overexpression of P-glycoprotein (Pgp) in tumor cells. However, some discrepancies still exist as to the clinical significance of Pgp in osteosarcoma. We sought to elucidate further whether the Pgp expression correlated with clinical behavior in a series of patients with osteosarcoma via high-throughput tissue microarray (TMA) analysis. Immunohistochemical analysis of Pgp expression in a TMA of 114 specimens with a retrospective review of 70 osteosarcoma patients admitted to the Massachusetts General Hospital (MGH) was performed. High Pgp expression was correlated with metastasis development and poor response to pre-operative chemotherapy in osteosarcoma patients. Eighteen of the fifty-seven patients initially admitted with primary osteosarcoma showed high Pgp expression. Among these 18 patients with high Pgp expression, 13 of 18 (72%) patients eventually developed metastases. There was no significant clinical relevance between Pgp expression and osteosarcoma survival. These results support that high expression of Pgp is important, but cannot be assigned as, an individual predictor in the development of human osteosarcoma.
© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1606-1612, 2016. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  P-glycoprotein (Pgp); metastasis; osteosarcoma; prognosis; tissue microarray (TMA)

Mesh:

Substances:

Year:  2016        PMID: 26790551     DOI: 10.1002/jor.23173

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  6 in total

Review 1.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

2.  Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma.

Authors:  Hangzhan Ma; Dylan C Dean; Ran Wei; Francis J Hornicek; Zhenfeng Duan
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-02-18       Impact factor: 5.346

3.  Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Authors:  Yunfei Liao; Slim Sassi; Stefan Halvorsen; Yong Feng; Jacson Shen; Yan Gao; Gregory Cote; Edwin Choy; David Harmon; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

Review 4.  Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.

Authors:  Tang Liu; Zhihong Li; Qing Zhang; Karen De Amorim Bernstein; Santiago Lozano-Calderon; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Oncotarget       Date:  2016-12-13

5.  TNF-α Modulates P-Glycoprotein Expression and Contributes to Cellular Proliferation via Extracellular Vesicles.

Authors:  Tandressa Berguetti; Lucas S P Quintaes; Thais Hancio; Marcela C Robaina; André L S Cruz; Raquel C Maia; Paloma Silva de Souza
Journal:  Cells       Date:  2019-05-24       Impact factor: 6.600

6.  Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival.

Authors:  José Manuel Casanova; Jani-Sofia Almeida; John David Reith; Luana Madalena Sousa; Ruben Fonseca; Paulo Freitas-Tavares; Manuel Santos-Rosa; Paulo Rodrigues-Santos
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.